Aglaia Therapeutics
A biotechnology startup developing promising new therapies that can overcome resistance to current targeted therapies in cancer patients.
Launch date
Market cap
-
Enterprise valuation
€16—24m (Dealroom.co estimates Sep 2021.)
Villejuif Île-de-France (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
€4.0m | Seed | ||
Total Funding | €4.0m |